Skip to main content


Fig. 1 | BMC Cancer

Fig. 1

From: IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway

Fig. 1

HCC cancer stem-like cells were successfully enriched from Hep3B, HepG2, and PLC cell lines. a Formation of spheres under the stem cell selective condition on day 8 after culturing from parental Hep3B, HepG2, and PLC cells is shown. b The mRNA expression levels of HCC cancer stem cell markers in parental Hep3B cells and their sphere cells were analyzed by qRT–PCR with actin as an internal control. Histograms represent means ± s.d. from three independent experiments (*, P < 0.05; **, P < 0.01). c Dose-dependent growth inhibition of parental Hep3B and HepG2 cells and their sphere cells upon continuous exposure to the indicated concentrations of doxorubicin for 48 h was measured by MTT assay. Each dosage point represents the mean ± s.e. from three independent experiments (*, P < 0.05; **, P < 0.01)

Back to article page